At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6 enrolled
Drug / intervention
valganciclovirdrug
Likely dose
Not stated in record
Key inclusion· 5
- ✓Histologically confirmed classic Kaposi's sarcoma involving skin, non-HIV-associated (HIV negative)
- ✓At least 8 KS lesions with ≥5 marker lesions measurable in 2 dimensions AND ≥3 other lesions ≥1 cm in diameter
- ✓Age ≥18 years
- ✓Karnofsky performance status 70-100%
Key exclusion· 4
- ✕Known active visceral KS or symptomatic KS-related edema requiring cytotoxic chemotherapy
- ✕Hypersensitivity to valganciclovir or ganciclovir
- ✕Other neoplasia requiring cytotoxic therapy
- ✕Pregnant or nursing
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma
In Brief
A clinical study evaluating valganciclovir for Sarcoma. Completed, enrolled 6 participants across 3 sites.
Detailed Summary
RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and may have a role in causing Kaposi's sarcoma. Valganciclovir is an antiviral drug that acts against many types of herpesviruses and may be an effective treatment for Kaposi's sarcoma. PURPOSE: This clinical trial is studying how well valganciclovir works in treating patients with classic non-HIV-associated Kaposi's sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2004
First PostedNov 2004
Primary CompletionFeb 2008
TodayJul 2026
First PostedNov 10, 2004
Enrollment StartApr 1, 2004
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 21.6 years ago
Interventions
valganciclovirdrug